DelveInsight’s “Cytomegalovirus (CMV) Infection- Epidemiology Insights-2023-EU5” Reports provides an overview of the disease and the historical and forecasted epidemiological data for the Cytomegalovirus (CMV) Infection in EU5 (France, Germany, Italy, Spain and United Kingdom) for 2013-2023.
According to DelveInsight, the total number of Diagnosed Cytomegalovirus (CMV) infection cases in France is expected to increase at a CAGR of 0.06% to 20,871 cases by 2023. In case of Germany it is expected to increase at a CAGR of 0.067% to 21,619 cases by 2023. In United Kingdom, the total number of Diagnosed Cytomegalovirus (CMV) infection cases is expected to increase at a CAGR of 0.061% to 14,417 cases by 2023 and in Spain is expected to increase at a CAGR of 0.029% to 12,810 cases in 2023. For Italy, it is expected to increase at a CAGR of 0.031% to 13,358 cases in 2023. CMV infection is most prevalent in Italy and least prevalent in Spain of the EU5.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
• Report covers the disease overview including etiology, pathophysiology, symptoms, diagnosis and disease management.
• Identifying patient populations in the European Cytomegalovirus (CMV) Infection market
• The Report covers the detailed historical and forecasted epidemiological data covering European from 2013-2023.
'
Cytomegalovirus Infections
Disease Overview
Symptoms of cytomegalovirus (CMV) Infection
Etiology
Risk Factors
Pathogenesis of human cytomegalovirus
Pathophysiology of cytomegalovirus infection
Diagnosis
Epidemiology and Patient Population
Europe
Italy
Total CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2015)
Total CMV Prevalent, Diagnosed and Treatable Cases: Forecasted Data (2016-2023)
CMV Patients among Transplants: Historical Data (2013-2015)
CMV Patients among Transplants: Forecasted Data (2016-2023)
Infants Patients at High Risk of CMV: Historical Data (2013-2015)
Infants Patients at High Risk of CMV: Forecasted Data (2016-2023)
HIV Patients at High Risk of CMV: Historical Data (2013-2015)
HIV Patients at High Risk of CMV: Forecasted Data (2016-2023)
Spain
Total CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2015)
Total CMV Prevalent, Diagnosed and Treatable Cases: Forecasted Data (2016-2023)
CMV Patients among Transplants: Historical Data (2013-2015)
CMV Patients among Transplants: Forecasted Data (2016-2023)
Infants Patients at High Risk of CMV: Historical Data (2013-2015)
Infants Patients at High Risk of CMV: Forecasted Data (2016-2023)
HIV Patients at High Risk of CMV: Historical Data (2013-2015)
HIV Patients at High Risk of CMV: Forecasted Data (2016-2023)
United Kingdom
Total CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2015)
Total CMV Prevalent, Diagnosed and Treatable Cases: Forecasted Data (2016-2023)
CMV Patients among Transplants: Historical Data (2013-2015)
CMV Patients among Transplants: Forecasted Data (2016-2023)
Infants Patients at High Risk of CMV: Historical Data (2013-2015)
Infants Patients at High Risk of CMV: Forecasted Data (2016-2023)
HIV Patients at High Risk of CMV: Historical Data (2013-2015)
HIV Patients at High Risk of CMV: Forecasted Data (2016-2023)
Germany
Total CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2015)
Total CMV Prevalent, Diagnosed and Treatable Cases: Forecasted Data (2016-2023)
CMV Patients among Transplants: Historical Data (2013-2015)
CMV Patients among Transplants: Forecasted Data (2016-2023)
Infants Patients at High Risk of CMV: Historical Data (2013-2015)
Infants Patients at High Risk of CMV: Forecasted Data (2016-2023)
HIV Patients at High Risk of CMV: Historical Data (2013-2015)
HIV Patients at High Risk of CMV: Forecasted Data (2016-2023)
France
Total CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2015)
Total CMV Prevalent, Diagnosed and Treatable Cases: Forecasted Data (2016-2023)
CMV Patients among Transplants: Historical Data (2013-2015)
CMV Patients among Transplants: Forecasted Data (2016-2023)
Infants Patients at High Risk of CMV: Historical Data (2013-2015)
Infants Patients at High Risk of CMV: Forecasted Data (2016-2023)
HIV Patients at High Risk of CMV: Historical Data (2013-2015)
HIV Patients at High Risk of CMV: Forecasted Data (2016-2023)
Unmet Medical Needs
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight
Table 1: Total CMV Prevalent, Diagnosed and Treatable Cases for Italy: Historical Data (2013-2015)
Table 2: Total CMV Prevalent, Diagnosed and Treatable Cases for Italy: Foreacasted Data (2017-2023)
Table 3: CMV Patients among Transplants in Italy: Historical Data (2013-2015)
Table 4: CMV Patients among Transplants in Italy: Foreacasted Data (2017-2023)
Table 5: Infants Patients at High Risk of CMV in Italy: Historical Data (2013-2015)
Table 6: Infants Patients at High Risk of CMV in Italy: Foreacasted Data (2017-2023)
Table 7: HIV Patients at High Risk of CMV in Italy: Historical Data (2013-2015)
Table 8: HIV Patients at High Risk of CMV in Italy: Foreacasted Data (2017-2023)
Table 9: Total CMV Prevalent, Diagnosed and Treatable Cases for Spain: Historical Data (2013-2015)
Table 10: Total CMV Prevalent, Diagnosed and Treatable Cases for Spain: Foreacasted Data (2017-2023)
Table 11: CMV Patients among Transplants in Spain: Historical Data (2013-2015)
Table 12: CMV Patients among Transplants in Spain: Foreacasted Data (2017-2023)
Table 13: Infants Patients at High Risk of CMV in Spain: Historical Data (2013-2015)
Table 14: Infants Patients at High Risk of CMV in Spain: Foreacasted Data (2017-2023)
Table 15: HIV Patients at High Risk of CMV in Spain: Historical Data (2013-2015)
Table 16: HIV Patients at High Risk of CMV in Spain: Foreacasted Data (2017-2023)
Table 17: Total CMV Prevalent, Diagnosed and Treatable Cases for United Kingdom: Historical Data (2013-2015)
Table 18: Total CMV Prevalent, Diagnosed and Treatable Cases for United Kingdom: Foreacasted Data (2017-2023)
Table 19: CMV Patients among Transplants in United Kingdom: Historical Data (2013-2015)
Table 20: CMV Patients among Transplants in United Kingdom: Foreacasted Data (2017-2023)
Table 21: Infants Patients at High Risk of CMV in United Kingdom: Historical Data (2013-2015)
Table 22: Infants Patients at High Risk of CMV in United Kingdom: Foreacasted Data (2017-2023)
Table 23: HIV Patients at High Risk of CMV in United Kingdom: Historical Data (2013-2015)
Table 24: HIV Patients at High Risk of CMV in United Kingdom: Foreacasted Data (2017-2023)
Table 25: Total CMV Prevalent, Diagnosed and Treatable Cases for Germany: Historical Data (2013-2015)
Table 26: Total CMV Prevalent, Diagnosed and Treatable Cases for Germany: Foreacasted Data (2017-2023)
Table 27: CMV Patients among Transplants in Germany: Historical Data (2013-2015)
Table 28: CMV Patients among Transplants in Germany: Foreacasted Data (2017-2023)
Table 29: Infants Patients at High Risk of CMV in Germany: Historical Data (2013-2015)
Table 30: Infants Patients at High Risk of CMV in Germany: Foreacasted Data (2017-2023)
Table 31: HIV Patients at High Risk of CMV in Germany: Historical Data (2013-2015)
Table 32: HIV Patients at High Risk of CMV in Germany: Foreacasted Data (2017-2023)
Table 33: Total CMV Prevalent, Diagnosed and Treatable Cases for France: Historical Data (2013-2015)
Table 34: Total CMV Prevalent, Diagnosed and Treatable Cases for France: Foreacasted Data (2017-2023)
Table 35: CMV Patients among Transplants in France: Historical Data (2013-2015)
Table 36: CMV Patients among Transplants in France: Foreacasted Data (2017-2023)
Table 37: Infants Patients at High Risk of CMV in France: Historical Data (2013-2015)
Table 38: Infants Patients at High Risk of CMV in France: Foreacasted Data (2017-2023)
Table 39: HIV Patients at High Risk of CMV in France: Historical Data (2013-2015)
Table 40: HIV Patients at High Risk of CMV in France: Foreacasted Data (2017-2023)
